Drug intelligence / Profile preview

pravastatin + chenodeoxycholic acid + metformin

Development stage: Unknown
Lead developer: Daiichi Sankyo
Modality: Small Molecules
Administration: Oral

Overview

This is a combination of three distinct medications that have been studied together in clinical research. Pravastatin is an HMG-CoA reductase inhibitor used to treat hypercholesterolemia. Chenodeoxycholic acid is a primary bile acid used for treating primary biliary cirrhosis. Metformin is a biguanide antihyperglycemic medication used as first-line treatment for type 2 diabetes. The combination has been studied to understand how metformin affects the pharmacokinetics of pravastatin and chenodeoxycholic acid through its repression of the bile salt export pump (BSEP).

Targets

HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)AMPK (Adenosine monophosphate–activated protein kinase)ND1 (Mitochondrial electron transport chain complex I)ABCB11 (Bile salt export pump)

Beyond the preview

Go deeper on pravastatin + chenodeoxycholic acid + metformin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on pravastatin + chenodeoxycholic acid + metformin.

Explore the full profile